Led by science
We are the only biopharma company founded and led by physician-scientists for our entire 30+ year history. From our first days, science was and remains our central guiding principle. Our leadership includes multiple Nobel Laureates and five members of the National Academy of Sciences, and we are one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.GET TO KNOW THE TEAM
Stories from our colleagues
Our colleagues have backgrounds as diverse as the problems we’re working to solve. Here are just a few of their stories:
Musical theater stages and Regeneron labs have more in common than you might think: both inspire a group of people to work together toward a common goal. Alyson works with the ophthalmology team to answer the important questions to ensure that patients are receiving the most effective treatments for them.
Dinko’s curiosity about the natural world inspired him to pursue a career in science. Now he uses imaging technology to innovate and positively impact the lives of patients with rare diseases like fibrodysplasia ossificans progressiva (FOP).
Our President and Chief Scientific Officer, George Yancopoulos, followed in the footsteps of his grandfather to pursue science. Watch to find out how he works every day to invent and discover the next new medicine that makes a difference in patient lives.
Biology is a complex puzzle, and scientists, like Jean, work to solve these puzzles by gathering and interpreting results that inform the creation of life-changing medicines. Jean shares how her passion for designing dresses led her to a career designing experiments at Regeneron.
When she was young, Petra wanted to be a veterinarian like her dad. But then she enjoyed working with people. Now, she is a Regeneron scientist finding ways to outsmart cancer with immuno-oncology.
Regeneron scientist Vishal followed his curiosity to a career studying antibodies to help bring medicine to people living with disease.
Clinical trials are crucial to determine if compounds are useful, effective and safe. Wilson oversees this process at Regeneron to ensure our clinical plans are executed in high quality.
Zack’s curiosity about the science behind our life-changing medicines led him to a career on our Industrial Operations and Product Supply (IOPS) team. His work is the scientific backbone of our product-supply facility.
Where innovative ideas begin
We design our research programs and novel technologies to help solve the human body’s most complex mysteries. Investing in basic research and ‘blue sky’ innovation lays the groundwork for every future treatment we invent. Our core capabilities for target discovery and validation are enabled by VelociSuite®, a series of proprietary antibody technologies that accelerate, improve and disrupt the traditional drug discovery and development process. Collectively, these and other novel technologies allow us to continuously shorten the average timelines from inception to approval.
Rapid response to infectious diseases
How can we go even faster? We have applied our VelociSuite® technologies in a 'rapid response' manner that parallel tracks certain steps and speeds hand-offs between groups in order to bring novel antibodies for infectious diseases to the world faster than ever. Decades of hard work have prepared us with unique expertise and capabilities to jump into action to address deadly pathogens like the viruses that cause Ebola, Middle East Respiratory Syndrome (MERS) and COVID-19.LEARN ABOUT OUR EFFORTS
On the frontier of antibody science and medicine
Not all antibodies are created equal. We consider ourselves pioneers in antibody medicine. Our deep biologics expertise and novel technologies have allowed us to discover, develop and manufacture numerous antibody medicines from beginning to end. We helped establish antibodies as an important class of medicine, but we’re not done yet. Find out about the antibodies of today and tomorrow.SEE OUR ANTIBODY RESEARCH
Citizens of science
Transparency is a hallmark of scientific progress. Our pioneering scientists regularly publish their research in leading scientific journals, including 200+ peer-reviewed publications in 2019.OUR LIBRARY OF PUBLICATIONS
See how our 2021 clinical pipeline advancements positioned us for growth
Join our team
MD, PhD, PharmD. Over 1,100 of our employees hold these prestigious degrees. Whether it’s in the laboratories or in the conference rooms, every physician-scientist at Regeneron brings valuable perspective and expertise – just ask our Chief Executive Officer and Chief Scientific Officer.career opportunities